

Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer

SUPPLEMENTARY MATERIALS

Supplementary Table 1: Treatment types in the Chemotherapy group (*n* = 223)

Characteristic	Number	Percent
Chemotherapy regimen		
Carboplatin + paclitaxel	70	31.4
Cisplatin + paclitaxel	33	14.8
Nedaplatin + irinotecan	25	11.2
Cisplatin + irinotecan	14	6.3
Carboplatin + docetaxel	13	5.8
Cisplatin + etoposide + mitomycin C	9	4.0
Cisplatin + bleomycin + vincristine + mitomycin C	8	3.6
Fluorouracil	7	3.1
Nedaplatin + ifosfamide	5	2.2
Nedaplatin alone	4	1.8
Carboplatin + paclitaxel + pirarubicin	3	1.3
Cisplatin + fluorouracil	3	1.3
Irinotecan + mitomycin C	3	1.3
Cisplatin + doxorubicin + cyclophosphamide	3	1.3
Nedaplatin + ifosfamide + peplomycin	3	1.3
Cisplatin + mitomycin C + peplomycin + vincristine	3	1.3
Nedaplatin + ifosfamide + bleomycin	2	0.9
Cisplatin + ifosfamide + epirubicin	2	0.9
Other regimens	13	5.8
Chemotherapy cycle		
1–2	15	6.7
3–4	105	47.1
5–6	91	40.8
> 6	2	0.9
n/a	10	4.5
Chemotherapy interval		
3 weeks	73	32.7
4 weeks	138	61.9
n/a	12	5.4
Chemotherapy delay		
No	170	76.2
Yes	37*	16.6
n/a	16	7.2
Chemotherapy discontinuation		
No	171	76.7
Yes	23	10.3
n/a	29	13.0

Supplementary Table 2: Treatment types in the CCRT group (*n* = 172)

Characteristic	Number	Percent
Radiosensitizer type		
Cisplatin	88	51.2
Nedaplatin	54	31.4
Fluorouracil	5	2.9
Cisplatin + fluorouracil	3	1.7
Others	6	3.5
n/a	16	9.3
Radiation dose (Gy)		
50.0	59	34.3
50.4	42	24.4
45.0	30	17.4
46.0	22	12.8
48.6	4	2.3
51.0	4	2.3
44.0	1	0.6
45.8	1	0.6
46.8	1	0.6
50.6	1	0.6
n/a	7	4.1

Supplementary Table 3: Patient demographics after propensity score matching

Characteristics	CCRT	Chemotherapy	P-value
No.	<i>n</i> = 99	<i>n</i> = 99	
Year			0.97
2004	14 (14.1%)	14 (14.1%)	
2005	15 (15.2%)	18 (18.2%)	
2006	23 (23.2%)	20 (20.2%)	
2007	27 (27.3%)	28 (28.3%)	
2008	20 (20.2%)	19 (19.2%)	
Age (mean ±SD)	45.0 (±10.4)	45.9 (±10.7)	0.54
Stage			0.99
IB1	77 (77.8%)	78 (78.8%)	
IB2	22 (22.2%)	21 (21.2%)	
Histology			0.89
Squamous	66 (66.7%)	63 (63.6%)	
Adenocarcinoma	25 (25.3%)	28 (28.3%)	
Adenosquamous	8 (8.1%)	8 (8.1%)	
Deep stromal invasion			0.99
No	27 (27.3%)	27 (27.3%)	
Yes	72 (72.7%)	72 (72.7%)	
Tumor size			0.61
≤ 4.0 cm	75 (75.8%)	79 (79.8%)	
> 4.0 cm	24 (24.2%)	20 (20.2%)	
LVSI			0.60
Not present	23 (23.2%)	19 (19.2%)	
Present	76 (76.8%)	80 (80.8%)	
Sampled lymph nodes			
Pelvic (median IQR)	29.5 (18)	28 (17)	0.93

Mean (± SD), median (interquartile range), or number (%) per column are shown. Student *t* test, Fisher exact test, chi-square test, or Mann-Whitney *U* test for *P*-values. Abbreviations: CCRT, concurrent chemoradiotherapy; and LVSI, lympho-vascular space invasion.